A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Pharmaceutica N.V., Belgium
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male 18 years of age or older
Participant with histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
Participant with documented metastatic prostate cancer
Participant with documented castration resistance with progression of prostate cancer on androgen deprivation therapy (ADT)
Participant who will be initiated on either abiraterone acetate or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that is asymptomatic or mildly symptomatic (per physician's evaluation) after failure of ADT at the time of treatment initiation
Participants who signed a participation agreement or Informed consent form (ICF) per local regulations
The treatment decision (abiraterone acetate or enzalutamide) by the treating physician must have been taken before enrollment into the study
Baseline patient-reported outcomes (PROs) must be captured before the first administration of abiraterone acetate or enzalutamide.
You may not be if
Patient who has received any chemotherapy/cytotoxic agent to treat their mCRPC before abiraterone acetate or enzalutamide initiation; or ; treat their metastatic hormone-sensitive prostate cancer (mHSPC) \<12 months prior to abiraterone acetate or enzalutamide initiation.
Participant who is not capable of completing a patient survey
Participant who has received or is currently receiving abiraterone acetate or enzalutamide
Patient receiving an investigational treatment for prostate cancer of any kind before or at the time of initiation of abiraterone acetate or enzalutamide
Participant who is currently included in other observational studies with abiraterone acetate sponsored by Janssen
Clareo Health | A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants
